Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703 · View on ClinicalTrials.gov ↗
Study Summary
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BGB-26808
Study Locations (20)
California
- City of Hope National Medical Center — Duarte
- University of Southern Californianorris Comprehensive — Los Angeles
New South Wales
- Southside Cancer Care — Miranda
- Macquarie University — North Ryde
Hubei
- Hubei Cancer Hospital — Wuhan
- Tongji Hospital,Tongji Medical College of Hustsino French New City Branch — Wuhan
Shandong
- Jining No1 Peoples Hospital West Branch — Jining
- Yantai Yuhuangding Hospital — Yantai
Connecticut
- Yale University, Yale Cancer Center — New Haven
Florida
- Sylvester Cancer Center, University of Miami — Miami
New Jersey
- John Theurer Cancer Center Hackensack University Medical Center — Hackensack
New York
- Icahn School of Medicine At Mount Sinai — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05981703
The ClinicalTrials.gov registry entry for NCT05981703 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeOne Medicines, which has 138 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions — of which Tislelizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05981703 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, New South Wales, Hubei. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05981703 about?
NCT05981703 is a clinical study titled "A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors". This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
What is the current status of trial NCT05981703?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2023-09-21. Estimated completion is 2027-09-30.
What conditions does trial NCT05981703 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05981703?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BGB-26808 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05981703?
This trial is sponsored by BeOne Medicines, which has 138 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05981703 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.